Drugs / OMS302
last change Sep 2016 re-read 2 minutes ago

OMS302

Developed for
cataract
Investigated by
Omeros Corporation

Trials 4 · a red edge is where a trial was stopped

20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT00721695 May 2008 → Feb 2009 cataract Omeros Corporation Completed No outcome recorded
Phase 21 trial
Phase 2 NCT01193127 Jul 2010 → Jan 2011 cataract Omeros Corporation Completed No outcome recorded
Phase 32 trials
Phase 3 NCT02132312 Jul 2014 → Sep 2016 cataract Omeros Corporation Completed No outcome recorded
Phase 3 NCT01454063 Sep 2011 → Mar 2012 Omeros Corporation Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as OMS302 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01454063
3

NCT02132312

NCT00721695

NCT01193127

Route Other “being developed as an irrigation solution during intracameral lens replacement surgical procedures of the eye” NCT00721695